Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Aug 16, 2013; 1(5): 166-168
Published online Aug 16, 2013. doi: 10.12998/wjcc.v1.i5.166
Published online Aug 16, 2013. doi: 10.12998/wjcc.v1.i5.166
Long lasting response to second-line everolimus in kidney cancer
Antonella Virtuoso, Tania Policastro, Michela Izzo, Piera Federico, Carlo Buonerba, Pasquale Rescigno, Giuseppe Di Lorenzo, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, 80131 Naples, Italy
Giuseppe Di Lorenzo, Deparment of Clinical Medicine, University Federico II of Naples, 80131 Naples, Italy
Author contributions: Virtuoso A, Policastro T, Izzo M and Buonerba C wrote the paper; all authors treated and followed up the patient, and gave their final approval to the manuscript.
Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Deparment of Clinical Medicine, University Federico II of Naples, Via Pansini, 5, 80131 Naples, Italy. giuseppedilorenzoncol@hotmail.com
Telephone: +39-8-17462114 Fax: +39-8-17462114
Received: May 1, 2013
Revised: July 2, 2013
Accepted: July 17, 2013
Published online: August 16, 2013
Processing time: 98 Days and 9 Hours
Revised: July 2, 2013
Accepted: July 17, 2013
Published online: August 16, 2013
Processing time: 98 Days and 9 Hours
Core Tip
Core tip: Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin pathway. Everolimus is recommended for the second line therapy of metastatic renal cell carcinoma after a Tyrosine kinase inhibitor. In the case presented here, everolimus was administered after first line therapy with sunitinib. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial.